Welcome to our dedicated page for Telix Pharmaceuticals American Depositary Shares news (Ticker: TLX), a resource for investors and traders seeking the latest updates and insights on Telix Pharmaceuticals American Depositary Shares stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Telix Pharmaceuticals American Depositary Shares's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Telix Pharmaceuticals American Depositary Shares's position in the market.
Telix Pharmaceuticals has completed the installation of two cyclotrons at its Manufacturing Solutions facility in Brussels South, Belgium. The facility will serve as the company's primary manufacturing site for the EMEA region, with production starting in 2025. One cyclotron will focus on clinical and commercial supply, while the other will be dedicated to R&D activities.
The facility, equipped with GE HealthCare and IBA cyclotrons and ARTMS' QUANTM Irradiation System™, will produce various medical isotopes including gallium-68, zirconium-89, fluorine-18, copper-64, and actinium-225. The company received an updated radiation license in 2022 from the Belgian Federal Agency for Nuclear Control. Commercial GMP production is expected to begin in H2 2025, following commissioning in early Q1 2025.
Telix Pharmaceuticals announces expansion of its theranostic pipeline with new FAP-targeting assets, focusing initially on bladder cancer treatment. The company has entered exclusive worldwide agreements for clinically validated FAP-targeting therapeutic and diagnostic radiopharmaceutical candidates developed at Johannes Gutenberg-Universität Mainz. The assets, tested in over 500 patients, feature enhanced tumor retention and reduced off-target uptake. The deal involves €7 million in initial cash payment, €3 million after 12 months, and up to €132 million in milestone payments, plus €20 million in commercial milestones and royalties.
Telix Pharmaceuticals (ASX: TLX; Nasdaq: TLX) announces the commencement of trading of its American Depository Shares (ADSs) on the Nasdaq Global Select Market under the ticker symbol 'TLX'. Each ADS represents one fully paid ordinary share, with no new shares issued as part of the listing. The company maintains its primary listing on ASX, with JPMorgan Chase Bank appointed as the depositary, custodian and registrar for the ADS program. Initial trading may be as existing shareholders transition their shares to ADSs.
Telix Pharmaceuticals has partnered with Eckert & Ziegler SE for cyclotron-based production of actinium-225, a key isotope for targeted alpha therapies (TATs). The collaboration combines EZAG's isotope technology with Telix's global manufacturing network to enhance production capacity for both development and commercial purposes. Alpha emitters like actinium-225 can deliver concentrated energy to cancer tissue while minimizing damage to surrounding healthy cells. Telix's TAT pipeline includes several clinical-stage candidates: TLX592 for prostate cancer, TLX252 for CAIX-targeting, TLX101 for brain cancer, and TLX300 for soft tissue sarcoma.
FAQ
What is the current stock price of Telix Pharmaceuticals American Depositary Shares (TLX)?
What is the market cap of Telix Pharmaceuticals American Depositary Shares (TLX)?
